

1 **Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor from the FDA**  
2 **Adverse Event Reporting System (FAERS)**

3 Alan Shi<sup>1</sup>; Harold Nguyen<sup>1</sup>; C. Benson Kuo<sup>2</sup>; Paul M. Beringer<sup>1,3\*</sup>

4 <sup>1</sup>Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences,  
5 University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90033, USA

6 <sup>2</sup>Department of Regulatory and Quality Sciences, Mann School of Pharmacy and Pharmaceutical  
7 Sciences, University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90033, USA

8 <sup>3</sup>USC Anton Yelchin CF Clinic, 1510 San Pablo St, Los Angeles, CA 90033, USA.

9 \* Corresponding author: 1985 Zonal Avenue, Los Angeles, CA 90033, USA, Tel: 323-442-1402,  
10 Fax: 323-442-1395, Email: [beringer@usc.edu](mailto:beringer@usc.edu)

11

12 **Keywords:** CFTR modulator, pharmacovigilance, FAERS, DILI, liver injury, KNIME

13

14 **Abstract**

15 **Introduction:** The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been  
16 established in prospective clinical trials. Liver function test elevations were observed in a greater  
17 proportion of patients receiving ETI compared with placebo; however, the relatively small  
18 number of patients and short duration of study preclude detection of rare but clinically significant  
19 associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-  
20 world risk of DILI associated with ETI through data mining of the FDA Adverse Event  
21 Reporting System (FAERS).

22 **Methods:** Disproportionality analyses were conducted on FAERS data from the fourth quarter of  
23 2019 through the third quarter of 2022. Comparative patient demographics, onset time and  
24 outcomes for ETI-DILI were also obtained.

25 **Results:** 452 reports of DILI associated with ETI were found, representing 2.1% of all adverse  
26 event reports for ETI. All disproportionality measures were significant for ETI-DILI at  $p < 0.05$ ;  
27 the reporting odds ratio (ROR) was comparable to that of drugs classified by FDA as “Most-  
28 DILI concern”. The most notable demographic finding was a male majority for ETI-DILI  
29 compared to a female majority for non ETI-DILI. Median ETI-DILI onset time was 50.5 days,  
30 and hospitalization was the second most common complication.

31 **Conclusion:** Using FAERS data, ETI was found to be disproportionality associated with DILI.  
32 Future research is needed to investigate the hepatotoxic mechanisms and assess potential  
33 mitigation strategies for ETI-induced hepatotoxicity.

## 34 **Article Highlights**

- 35 • Using the FDA Adverse Event Reporting System database, ETI and DILI were found to  
36 be significantly associated ( $p < 0.05$ ) for all disproportionality measures (PRR, ROR, IC,  
37 EGBM, Yates' chi-squared).
- 38 • The ROR for ETI-DILI is greater than that of many "Most-DILI concern" drugs in the  
39 FDA DILIRank dataset but is not within the top 20 drugs associated with DILI.
- 40 • Patient reports for ETI-DILI were predominately male, in contrast to patient reports for  
41 other drugs and DILI.
- 42 • "Hospitalization" was the second most common patient outcome for ETI-DILI after  
43 "other serious outcomes".
- 44 • Most patients had onset times within 3 months of initiation, several patients had an onset  
45 time greater than 1 year.
- 46 • Onset times indicate that liver function test monitoring should be initiated earlier than 3  
47 months and potentially extend beyond 1 year in some patients.

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

## 63 1. Introduction

64 Elexacaftor/tezacaftor/ivacaftor (ETI, brand name: Trikafta) is a cystic fibrosis transmembrane  
65 conductance regulator (CFTR) modulator which acts as a triple combination protein corrector-  
66 potentiator therapy. Clinical trials have shown that ETI is highly efficacious in improving lung  
67 function and nutritional status in people with cystic fibrosis and is well tolerated with few safety  
68 concerns (1-6). However, periodic monitoring is recommended due to the increased incidence of  
69 liver function test abnormalities identified in clinical trials as well as in case reports of drug-  
70 induced liver injury (DILI) (1-8). DILI due to ETI can be predicted in part by its  
71 physicochemical properties. The Biopharmaceutical Classification System (BCS) classifies drugs  
72 according to permeability and solubility. Among the compounds in ETI, ivacaftor and tezacaftor  
73 fall under the Biopharmaceutical Classification System (BCS) Class 2, based on high  
74 permeability and low solubility (9, 10). Compounds in Class 2 of BCS and the similar  
75 Biopharmaceutical Drug Disposition Classification System (BDDCS) are considered to have the  
76 highest DILI risk compared to other classes (11).

77 Consistent with the predicted DILI risk for BCS Class 2, Phase III clinical trials showed  
78 evidence of DILI due to ETI, including elevation in ALT/AST > 5X the upper limit of normal  
79 (ULN) or ALT/AST > 3X ULN with bilirubin > 2X ULN in the absence of other causes such as  
80 hepatitis or alcoholic liver disease (1-6). Results from one of the pivotal phase 3 trials showed  
81 that the incidence of maximum transaminase elevations above 8X, 5X, or 3X the upper limit of  
82 normal (ULN) occurred in 1%, 2%, and 8% of ETI-treated patients compared to 1%, 1%, and 5%  
83 for placebo, while the incidence of maximum total bilirubin above 2X ULN occurred in 4% of  
84 ETI-treated patients compared to <1% for placebo (1). In real-world use, DILI occurring after  
85 ETI administration has resulted in several cases of severe outcomes for patients, including acute  
86 liver failure requiring transplantation and a case of hepatic necrosis (12-14). A limitation of  
87 Phase III trials is their relatively small sample size and short term follow up which cannot  
88 capture rare safety concerns that may be revealed in a longer-term, larger pool of real-world  
89 patients.

90 Despite the predictive risk of DILI due to ETI's physicochemical properties and evidence of  
91 DILI associated with ETI in clinical trials and post-marketing surveillance, a statistical  
92 association between ETI and DILI in real-world use has not been established. While the FDA has  
93 created DILrank, a dataset of 1,036 FDA-approved drugs divided into four classes based on  
94 their potential for causing DILI, elexacaftor, tezacaftor, and ivacaftor are noticeably absent from  
95 this vital resource (15). The analysis of large adverse event databases, such as the FDA Adverse  
96 Event Reporting System (FAERS), can improve understanding of the ETI-DILI relationship by  
97 detecting and determining the strength of disproportionality signals for ETI-DILI and identifying  
98 DILI-related safety concerns of ETI that may be missed in clinical trials and case reports. This  
99 study aims to shed light on the real-world risk of DILI associated with ETI along with relevant  
100 demographic and patient outcome trends related to ETI-DILI through the data mining of FAERS  
101 quarterly data reports three years from the approval of ETI in the US market, from Q4 2019 to  
102 Q3 2022, inclusive (16).

## 104 **2. Methods**

### 105 *2.1 Source of Data*

106 The FDA Adverse Event Reporting System (FAERS) database supports FDA's post-marketing  
107 surveillance for drugs and biologics and contains reports of adverse events, medication errors,  
108 and product quality complaints (17). Reports in FAERS may be submitted by healthcare  
109 professionals, consumers, and manufacturers to the MedWatch website to be compiled in  
110 FAERS (17). FAERS is structured into several datasets containing drug information (DRUG),  
111 demographic information (DEMO), patient outcomes (OUTC), indications (INDI), adverse  
112 reactions (REAC) and drug therapy start dates and end dates (THER). The datasets are linked  
113 through a primary identification number (PRIMARYID). Definitions of the outcome codes from  
114 the MedWatch form instructions are included in Supplement S1 (18).

115 FAERS data from the fourth quarter of 2019 through the third quarter of 2022 were analyzed  
116 using the data analytics platform, KNIME (Version 4.7.3), and Microsoft Excel (16, 19).  
117 Specifically, the DEMO, THER, INDI, DRUG, and REAC files were utilized to formulate a  
118 contingency table and OUTC was used to analyze outcome data. The data analysis process  
119 involved file merging, deduplication, categorization of the reports into a contingency table, and  
120 post-grouping statistical analysis. A PDF of the KNIME data analysis workflow can be found in  
121 Supplement S2, and the KNIME workflow files can be found in Supplement S3.

### 122 *2.2 File Merging*

123 The 12 quarters of data for each of the DEMO, THER, INDI, DRUG, REAC, and OUTC .txt  
124 files were merged using the command prompt in Windows. The merged DEMO, THER, INDI,  
125 DRUG, REAC, and OUTC .txt files were uploaded to KNIME and the rows with column  
126 headers such as "primaryid" were removed with a row filter exclusion. The files were then  
127 converted to CSV using KNIME to begin the deduplication process. Duplicates may occur  
128 because of redundant reports submitted by different sources (such as drug manufacturers,  
129 patients, and healthcare providers), and reoccurrences of the same report across multiple quarters  
130 due to follow-ups of the original case.

### 131 *2.3 Deduplication*

132 Cases in the FAERS database are represented by a numerical CASEID and a numerical  
133 PRIMARYID, a combination of the CASEID and Case Version number. The first deduplication  
134 step involves keeping only the latest PRIMARYID for any set of CASEID duplicates. The  
135 second deduplication step (based on Khaleel et al., 2022) is performed by removing event entries  
136 that match in all the following 8 categories: event date, patient age, patient sex, reporter country,  
137 list of start dates, list of indications, list of active ingredients, and list of preferred terms of  
138 adverse events (20). In other words, two reports will be considered as one if they match in the  
139 above 8 categories, even if they possess distinct CASEIDs. Note that reports lacking age data are  
140 treated as distinct entities.

141 As the DEMO data has unique PRIMARYIDs, deduplication began with this database, then the  
142 deduplicated DEMO was combined with the other data sets to eliminate all duplicate

143 PRIMARYIDs. Sorted lists of start dates, indications, active ingredients, and preferred terms are  
144 created with GroupBy nodes and merged with the DEMO data to allow for Duplicate Row Filter  
145 to find additional duplicates. Finally, any duplicates from this filter that are missing age are  
146 added back into the pool of events.

147 The deduplicated unique data was used to create a contingency table that categorizes each  
148 adverse reaction into one of four categories: ETI-DILI, ETI-not DILI, not ETI-DILI, not ETI-not  
149 DILI. To search for entries that include our drug of interest, several nodes were used to find  
150 active ingredients (the prod\_ai column in the FAERS data) that matched  
151 “ELEXACAFTOR/IVACAFTOR/TEZACAFTOR” or “ELEXACAFTOR”, or drug names  
152 matching “TRIKAFTA” or “KAFTRIO”.

153 Prior to the drug search, the REAC dataset was modified by replacing related liver injury  
154 preferred terms to “DILI”. Table 1 lists a dictionary of preferred terms for liver injury from the  
155 Medical Dictionary for Regulatory Activities (MedDRA), obtained from a prior study  
156 investigating antifungal drugs and DILI (21). Multiple instances of “DILI” per patient, resulting  
157 from the patient having multiple preferred terms that translate to “DILI”, were removed from the  
158 sample. This list of preferred terms was used for the deduplication of DEMO. The list of  
159 translated reactions is cross referenced with the list of ETI matches, leading to a completed  
160 contingency table, shown in Table 2.

161

<b>Preferred Terms (PT)</b>
Alanine aminotransferase abnormal
Alanine aminotransferase increased
Ammonia increased
Aspartate aminotransferase abnormal
Aspartate aminotransferase increased
Bile duct damage
Biliary cholangitis
Bilirubin conjugated increased
Bilirubin urine
Blood bilirubin abnormal
Blood bilirubin increased
Blood bilirubin unconjugated increased
Cholestasis
Cirrhosis
Coma hepatic
DILI
Drug-induced liver injury
Hepatic cirrhosis
Hepatic damage
Hepatic disease

Hepatic encephalopathy
Hepatic enzyme abnormal
Hepatic enzyme increased
Hepatic failure
Hepatic function abnormal
Hepatic injury
Hepatic necrosis
Hepatic steatosis
Hepatic vascular injury
Hepatitis
Hepatobiliary disease
Hepatocellular damage
Hepatocellular injury
Hepatomegaly
Hepatopathy
Hepatotoxicity
Hyperammonaemia
Hyperbilirubinaemia
Icterus
Jaundice
Liver damage
Liver fatty infiltration
Liver function test abnormal
Liver injury
Liver necrosis
Liver transplant
Mixed hepatocellular-cholestatic injury
Nonalcoholic fatty liver disease
Portal hypertension
Steatohepatitis
Transaminases abnormal
Transaminases increased
Urine bilirubin increased

162 **Table 1.** Dictionary of Preferred Terms for Liver Injury (21)

163 *2.4 Demographic Extrapolation*

164 Once categorized into ETI-DILI, ETI-not DILI, not ETI-DILI, not ETI-not DILI, the adverse  
165 reaction reports were grouped for each patient to collect demographic data, as one PRIMARYID  
166 can correspond to multiple adverse events, start dates, end dates, and outcomes. Thus, a patient  
167 could contribute to the statistics of multiple contingency table groups. Ages and weights were  
168 converted to all have units of years and kilograms, respectively, based on their corresponding

169 codes. When calculating descriptive statistics for age and weight, cutoffs of 0-115 years of age  
170 and 0-300 kg weight were introduced to exclude biologically implausible values that may have  
171 been entered erroneously. Outcome codes were also tabulated for the patients, counted as unique  
172 instances of each code (a patient could have both “Other Serious Outcome” and  
173 “Hospitalization” counted, but two “Hospitalization” events would be counted once). Definitions  
174 of the outcome codes from the instructions for completing MedWatch forms are included in  
175 Supplement S1 (18). Onset times for events were calculated only for Group A and only if a full  
176 date (YYYYMMdd) was available for event date and start date, with a cutoff minimum date of  
177 20190101.


## 178 *2.5 Statistical Analysis*

179 Several quantitative measures of correlation between ETI use and DILI reports were used,  
180 including proportional reporting ratio (PRR), reporting odds ratio (ROR), Yates’ chi-squared test  
181 ( $\chi^2_{\text{yates}}$ ), the information component (IC), and the empirical Bayesian geometric mean (EBGM).

182 PRR is a measure of the disproportionality of reporting of an adverse event for a product of  
183 interest in comparison to the same adverse event for all other products in the database. ROR is  
184 the odds of an adverse event occurring for a product of interest compared to the odds of that  
185 event occurring for all other products in the database. EBGM is a Bayesian statistical analysis  
186 that is similar to PRR but produces disproportionality scores toward the null. For PRR, ROR, and  
187 EBGM, statistically significant signals occur when the lower limit of the 95% confidence  
188 interval (CI) is greater than 1. Yates’ chi-squared test measures the degree of difference between  
189 the observed and expected number of reports for a drug-event combination, corrected for the  
190 assumption that the binomial frequencies from the contingency table can be approximated by the  
191 continuous chi-square distribution. The minimum criteria for adverse event safety signals  
192 established by Evans et al. (2002) is a PRR of at least 2, chi-squared of at least 4, and 3 or more  
193 or cases (22).

194 IC measures the disproportionality between the observed and expected number of reports for a  
195 drug-event combination, such as ETI-DILI for this study. Positive IC results from a higher  
196 number of observed reports than expected reports, while negative IC results from a lower  
197 number of observed reports than expected reports. Statistically significant signals occur when the  
198 95% CI does not contain 0.





199

200 **Figure 1.** Flowchart of FAERS data manipulation steps with the number of reports shown in  
201 bold.

### 202 3. Results

#### 203 3.1 Descriptive Analysis

204 There were 13,576,720 adverse reaction reports considered after deduplication, yielding 20,989  
205 reports containing ETI in the associated drug list. Among the ETI reports, 452 (2.1%) were  
206 considered DILI related. A contingency table of the reports and Bayesian analysis metrics are  
207 shown in Table 2. Demographic data on the categorized reports are shown in Table 3. Most  
208 patients in the intersection of ETI and DILI were male (61% vs 37%), while the other adverse  
209 reactions had more females than males.

#### 210 3.2 Disproportionality Analysis

211 The PRR was 3.38 (95% CI: 3.08-3.70), indicating an increased reporting rate of DILI with ETI  
212 use compared to DILI with non-ETI drugs. The ROR was 3.44 (95% CI: 3.13-3.77), also  
213 suggesting an increased likelihood of ETI patients experiencing DILI compared to all other  
214 drugs. Similarly, the EBGM of 3.37 (95% CI lower bound: 3.12) also showed a signal for  
215 increased reporting of DILI while taking ETI.

	<b>ETI</b>	<b>Not ETI</b>	<b>Total</b>
<b>DILI</b>	452 (A)	86268 (B)	86720 (A + B)
<b>Not DILI</b>	20537 (C)	13469463 (D)	13490000 (C + D)
<b>Total</b>	20989 (A + C)	13555731 (B + D)	13576720 (A+ B + C + D)

216



Measure of Disproportionality	Value
PRR (95% CI)	3.38 (3.08, 3.71)
ROR (95% CI)	3.44 (3.13, 3.77)
EBGM (95% CI lower bound)	3.37 (3.12)
Yates' Chi-squared	757.61
IC (95% CI)	1.75 (1.59, 1.86)

217 **Table 2.** Contingency table and disproportionality analysis for ETI-induced DILI.

218

	ETI, DILI (A)	ETI, Not DILI (C)	Not ETI, DILI (B)	Not ETI, Not DILI (D)
<b>N (patients)</b>	452	8569	86268	4522904
<b>Sex (n)</b>				
F	168 (37%)	4601 (54%)	42703 (50%)	2291612 (51%)
M	240 (53%)	3421 (40%)	32392 (38%)	1632874 (36%)
Blank	44 (10%)	546 (6%)	11164 (13%)	597008 (13%)
Other (U, P, I, T)	0 (0%)	1 (0%)	9 (0%)	1410 (0%)
<b>Age (years)</b>				
Median (IQR)	27 (16-38)	26 (18-37)	57 (42-68)	59(43-70)
Mean [SD]	28.86 [14.99]	29.04 [14.71]	53.31 [19.93]	55.32 [20.11]
Missing or Excluded	187	3933	26510	2088609
<b>Weight (kg)</b>				
Median (IQR)	58 (49-68)	59 (50-70)	70 (57-85.5)	73 (60-89)
Mean [SD]	58.86 [15.72]	60.83 [17.82]	71.58 [25.11]	75.19 [26.19]
Missing or Excluded	307	6160	60075	3762110
<b>Age Distribution (n)</b>				
<0 (excluded)	0 (0.00%)	0 (0.00%)	0 (0.00%)	21 (0.00%)
0-18	75 (16.59%)	1083 (12.64%)	4057 (4.70%)	141207 (3.12%)
18-29	70 (15.49%)	1607 (18.75%)	3855 (4.47%)	170252 (3.76%)
30-49	97 (21.46%)	1434 (16.73%)	14165 (16.42%)	490508 (10.84%)
50-64	14 (3.10%)	378 (4.41%)	18358 (21.28%)	723954 (16.01%)
65-74	7 (1.55%)	103 (1.20%)	11903 (13.80%)	510356 (11.28%)
75-84	2 (0.44%)	30 (0.35%)	5859 (6.79%)	305606 (6.76%)
85-115	0 (0.00%)	1 (0.01%)	1561 (1.81%)	92412 (2.04%)
>115 (excluded)	0 (0.00%)	0 (0.00%)	1 (0.00%)	46 (0.00%)
Missing	187 (41.37%)	3933 (45.90%)	26509 (30.73%)	2088542 (46.18%)


219 **Table 3.** Demographic Data of Categorized Events

220

Outcome	ETI, DILI	% patients with outcome	ETI, Not DILI	% patients with outcome
Missing	205	45%	4675	55%
Congenital Anomaly	2	1%	26	0%
Death	13	4%	171	2%
Disability	1	0%	30	0%
Hospitalization	124	38%	2727	32%
Life-threatening	7	2%	38	0%
Other Serious Outcome	193	60%	1604	19%
Required Intervention	0	0%	4	0%
<b>Total</b>	<b>545</b>	<b>N/A</b>	<b>9275</b>	<b>N/A</b>

221 **Table 4.** Complications for Patients Receiving ETI

222



223

224 **Figure 2.** Frequency distribution of onset time for DILI after ETI initiation.

225

Adverse Reaction	Count
Alanine aminotransferase increased	27

Aspartate aminotransferase increased	24
Drug-induced liver injury	23
Hepatic enzyme increased	22
Infective pulmonary exacerbation of cystic fibrosis	20
Abdominal pain	13
Gamma-glutamyltransferase increased	11
Hepatic cirrhosis	11
Weight decreased	11
Blood bilirubin increased	10
Blood alkaline phosphatase increased	9
Hepatic encephalopathy	9
Hepatic failure	9
Hepatic necrosis	9
Pyrexia	9
Respiratory disorder	9
Abdominal discomfort	8
Acute kidney injury	8
Dry eye	8
Exercise tolerance decreased	8

226 **Table 5.** Top 20 Adverse Reactions of Hospitalized Patients in Group A (ETI + DILI)

## 227 **4. Conclusion**

228 Based on the data from the FDA Adverse Event Reporting System database, ETI has been shown  
229 to be significantly associated with DILI for all the given measures of statistical  
230 disproportionality, including PRR, ROR, IC, EGBM, and Yates' chi-squared. The lower bound  
231 of the 95% confidence interval for the PRR, ROR, and IC of the ETI-DILI association were all  
232 greater than 1 (and greater than 0 in the case of IC), indicating that the association between ETI  
233 and DILI is statistically significant with  $p < 0.05$ . The Yates' chi-squared statistic of 757.61 was  
234 far greater than the critical value (10.828) for 1 degree of freedom at  $p < 0.001$ , indicating a  
235 highly significant association between ETI and DILI. Most importantly, ETI and DILI clearly  
236 exceeded the minimum requirement for adverse event safety signals ( $PRR \geq 2$ ,  $\text{chi-squared} \geq 4$ ,  $n$   
237  $\geq 3$ ) (22).

### 238 *4.1 Demographics*

239 The demographic data of the contingency table reveal notable differences between the four  
240 groups. The proportion of male to female patients for the ETI-DILI group (53% M, 37% F) is  
241 higher than that the ETI-not DILI group (40% M, 54% F), the not ETI-DILI group (38% M, 50%  
242 F), and the not ETI-not DILI group (36% M, 51% F). The higher proportion of males to females  
243 (3:2) in group the ETI-DILI group is notable because it runs counter to the evidence that women  
244 have been found to be more susceptible than men to DILI (23). Comparing the age across groups  
245 revealed that the ETI groups tended to be younger (median age 27 and 26, respectively) than  
246 non-ETI groups (median age 57 and 59, respectively), consistent with cystic fibrosis being

247 detected in children and being treated as early as possible. Patient weight followed a similar  
248 pattern: the ETI groups tended to have lower weight (median weight 58 kg and 59 kg,  
249 respectively) than non-ETI groups (median weight 70 kg and 73 kg, respectively). The lower  
250 weight in ETI groups may be due to the younger age of the ETI groups and/or cystic fibrosis-  
251 related malnutrition that has not been fully offset by ETI.

#### 252 *4.2 Monitoring*

253 The calculated onset time of DILI for ETI and the distribution of outcomes from the two ETI  
254 groups (A and C) shows that DILI tended to occur in patients less than 6 months after taking ETI  
255 and that a significant portion of patients required hospitalization. The calculated median onset  
256 time of 50.5 days (interquartile range: 18 - 149 days) and the mean of 113.3 days (SD = 155.7  
257 days) suggest that the typical onset time for DILI after ETI administration is approximately 2 to  
258 4 months, matching the package insert guidance to monitor for elevated liver function tests every  
259 3 months during the first year of treatment (24). However, most patients (62%, 72 out of 116)  
260 had an onset time less than 3 months (90 days) and many patients (41%, 48 out of 116) had an  
261 even shorter onset time less than one month (30 days). A notable minority of patients (7%, 8 out  
262 of 116) experienced onset times greater than 1 year, with the longest being over 800 days (Figure  
263 2). Thus, the data for early-onset and late-onset DILI due to ETI suggests that clinicians should  
264 monitor for DILI within one month after starting ETI and should remain vigilant for rare but  
265 potentially significant DILI events past the one-year window, since a significant portion of these  
266 events resulted in hospitalization. “Hospitalization” was the second most common patient  
267 outcome at a rate of 38% among the ETI-DILI group and 32% among the ETI-non DILI group  
268 (Table 4). Compiling the top 20 adverse reactions of hospitalized patients in the ETI-DILI group  
269 revealed that the top 4 adverse reactions were preferred terms for DILI, while the 5<sup>th</sup> was  
270 “infective pulmonary exacerbation of cystic fibrosis” (Table 5). Other non-DILI adverse  
271 reactions were also part of the top-20 list, suggesting that the high rate of hospitalization was not  
272 exclusively due to ETI-induced DILI.

#### 273 *4.3 Comparison with Other Drugs*

274 The ROR for ETI and DILI is greater than that of many drugs among the 192 classified as  
275 “Most-DILI concern” in the National Center for Toxicological Research Liver Toxicity  
276 Knowledge Base (NCTR-LTKB) DILrank dataset (15, 25). This aligns with the prediction of  
277 DILI risk from BDDCS, as Class 2 drugs such as ETI represent 53.6% of the “Severe DILI”  
278 category (acute liver failure, fatal hepatotoxicity, and discontinued and withdrawn), while Class  
279 1, 3, and 4 represent 28.6%, 14.3%, and 3.6%, respectively (11). In addition, the high dosage and  
280 extensive hepatic metabolism ( $\geq 50\%$ ) of ETI are factors identified by FDA as strongly  
281 associated ( $p < 0.05$ ) with increased DILI risk (26). Nonetheless, the ROR of ETI-DILI, 3.44  
282 (95% CI: 3.13 – 3.77), is still lower than that of many drugs currently on the market that are  
283 prescribed for people with cystic fibrosis, such as rifampin, 18.64 (17.54 – 19.82), atorvastatin,  
284 4.479 (4.358 – 4.604), clarithromycin, 4.809 (4.538 – 5.096), itraconazole, 5.552 (5.097 –  
285 6.048), voriconazole, 6.229 (5.79 – 6.702), and ciprofloxacin, 3.272 (3.095–3.459). In all,  
286 although ETI’s ROR of 3.44 surpasses that of numerous drugs in the “Most-DILI concern”  
287 category in DILrank, it does not rank in the top 20 drugs associated with DILI (25).

#### 288 4.4 Limitations

289 Limitations of the study include incomplete data from the FAERS database. For example, across  
290 all 4 groups of the contingency table, 6-13% of the patients' sex was left blank. In addition, it  
291 was common for patient reports in the database to lack a recorded outcome measure, as  
292 evidenced by missing outcomes for 43% of patients in the ETI-DILI group and 55% of patients  
293 in the ETI-not DILI group. There may also be other potential covariates that could cause DILI in  
294 the ETI-DILI group, including coadministered drugs (such as acetaminophen) and preexisting  
295 liver disease/other conditions, as well as factors not available in FAERS, such as alcohol/illicit  
296 drug use. Therefore, data from FAERS can only be used to assess the association between ETI  
297 and DILI, not causation (27). Despite these limitations, the data show that ETI and DILI are  
298 disproportionally associated compared to all other drugs and all other adverse reactions; the risk  
299 of DILI for ETI with or without other drugs is significantly higher than the overall risk of DILI  
300 for all other drugs in FAERS.

#### 301 4.5 Novelty of KNIME

302 Traditionally, script-based programming languages such as Python and SAS have been used to  
303 screen and analyze the FAERS database. For example, Python has been used to analyze FAERS  
304 data for a pharmacovigilance study of SARS-CoV-2 therapies and SAS has been used to mine  
305 FAERS data to determine the statistical association between dipeptidyl peptidase-4 and venous  
306 thromboembolism (28, 29). Though they are effective and efficient tools to conduct data mining  
307 studies, the need to be proficient in programming results in a high entry barrier for analyzing  
308 databases such as FAERS. Alternatively, visual programming software would be more  
309 preferable and appropriate for a broader scientific audience. One such program is KNIME, the  
310 Konstanz Information Miner, a free and open-source data analysis platform. KNIME has been  
311 used to analyze databases other than FAERS for a variety of applications within pharmaceutical  
312 and life sciences, such as searching the Protein Data Bank to support ligand- and structure-based  
313 drug design, and parsing genomic reference databases to identify and quantify microorganisms  
314 from the metagenomes of microbial communities (30, 31). To our knowledge, this study has  
315 been the first use of KNIME for performing disproportionality analyses on adverse event data  
316 from the FAERS database. Our KNIME workflow is available in Supplement S3 and can be  
317 adapted and reused to find association of other drugs with DILI.

#### 318 4.6 Summary and Future Directions

319 In summary, data mining the FAERS database using KNIME found that the association between  
320 ETI and DILI is statistically significant across all the major measures of disproportionality  
321 analysis, including PRR, ROR, IC, EBGGM, and Yates' chi-squared. The ROR of the ETI-DILI  
322 association would place ETI among the 192 drugs listed as "Most-DILI concern" in the NCTR-  
323 LTKB DILIRank dataset, but not within the top 20 drugs on the list. Nevertheless, the high rate of  
324 hospitalization among the ETI-DILI group in the FAERS data underscores the necessity to  
325 carefully monitor cystic fibrosis patients taking ETI and initiate interventions to avoid DILI.  
326 While the association between ETI and DILI has been established from real-world data in  
327 FAERS, future studies are needed to establish the causal relationship between ETI and DILI by

328 investigating the mechanisms of ETI-induced DILI. Additional research is also needed to assess  
329 potential mitigation strategies including ETI dose reduction and/or discontinuation to determine  
330 the efficacy and safety of these approaches (32).

331 **Author Contributions:** Conceptualization, A.S. and P.M.B.; Data curation, A.S. and H.N.;  
332 Formal analysis, A.S. and H.N.; Funding acquisition, P.M.B.; Investigation, A.S. and H.N.;  
333 Methodology, A.S. and H.N.; Resources, P.M.B.; Software, A.S. and H.N.; Supervision, P.M.B.,  
334 B.K.; Validation, A.S. and H.N.; Writing—original draft, A.S. and H.N.; Writing—review and  
335 editing, A.S., H.N., B.K., and P.M.B.

336 **Note:** Supplement S3 can be found online at <https://tinyurl.com/etidiliS3>

337 **Funding source:** This work was supported by the Anton Yelchin Foundation.

338 **Conflict of interest statement:** All authors declared no competing interests for this work.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353



354 **References**

- 355 1. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al.  
356 Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J*  
357 *Med.* 2019;381(19):1809-19.
- 358 2. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al.  
359 Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in  
360 people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised,  
361 phase 3 trial. *Lancet.* 2019;394(10212):1940-8.
- 362 3. Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, et al.  
363 Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor  
364 in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre,  
365 randomised, double-blind, active-controlled, phase 3b trial. *Lancet Respir Med.* 2022;10(3):267-  
366 77.
- 367 4. Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al.  
368 Triple Therapy for Cystic Fibrosis. *N Engl J Med.* 2021;385(9):815-25.
- 369 5. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A  
370 Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of  
371 Age with Cystic Fibrosis and at Least One. *Am J Respir Crit Care Med.* 2021;203(12):1522-32.
- 372 6. Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, et al. Efficacy  
373 and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with  
374 Cystic Fibrosis Heterozygous for. *Am J Respir Crit Care Med.* 2022;206(11):1361-9.
- 375 7. Tewkesbury DH, Athwal V, Bright-Thomas RJ, Jones AM, Barry PJ. Longitudinal  
376 effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis  
377 centre. *J Cyst Fibros.* 2023;22(2):256-62.
- 378 8. Lowry S, Mogayzel PJ, Oshima K, Karnsakul W. Drug-induced liver injury from  
379 elexacaftor/ivacaftor/tezacaftor. *J Cyst Fibros.* 2022;21(2):e99-e101.
- 380 9. Bocci G, Oprea TI, Benet LZ. State of the Art and Uses for the Biopharmaceutics Drug  
381 Disposition Classification System (BDDCS): New Additions, Revisions, and Citation  
382 References. *AAPS J.* 2022;24(2):37.
- 383 10. Multi-discipline review, elexacaftor/tezacaftor/ivacaftor: US Food and Drug  
384 Administration: Center for Drug Evaluation and Research; 2019 [Available from: [https://www-  
385 accessdata-fda-  
386 gov.libproxy2.usc.edu/drugsatfda\\_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf](https://www-accessdata-fda-gov.libproxy2.usc.edu/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf).  
387 11. Chan R, Benet LZ. Evaluation of DILI Predictive Hypotheses in Early Drug  
388 Development. *Chem Res Toxicol.* 2017;30(4):1017-29.
- 389 12. Sharma P, Giddings OK. Acute Liver Failure in a Patient with Cystic Fibrosis Taking  
390 Triple Combination Modulator. *Challenging Cases in Patients with Bronchiectasis. American*  
391 *Thoracic Society International Conference Abstracts: American Thoracic Society; 2021. p.*  
392 *A2113-A.*
- 393 13. Salehi M, Iqbal M, Dube A, AlJoudeh A, Edenborough F. Delayed hepatic necrosis in a  
394 cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio). *Respir Med Case Rep.*  
395 2021;34:101553.
- 396 14. Smith M, Ryan KJ, Gutierrez H, Sanchez LHG, Anderson JN, Acosta EP, et al. Ivacaftor-  
397 elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. *J Cyst Fibros.*  
398 2022;21(1):e8-e10.



- 399 15. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIRank: the largest reference  
400 drug list ranked by the risk for developing drug-induced liver injury in humans. *Drug Discov*  
401 *Today*. 2016;21(4):648-53.
- 402 16. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files [Internet].  
403 U.S. Food and Drug Administration. 2023. Available from: [https://fis.fda.gov/extensions/FPD-](https://fis.fda.gov/extensions/FPD-ODE-FAERS/FPD-ODE-FAERS.html)  
404 [ODE-FAERS/FPD-ODE-FAERS.html](https://fis.fda.gov/extensions/FPD-ODE-FAERS.html).
- 405 17. Questions and Answers on FDA's Adverse Event Reporting System (FAERS): U.S. Food  
406 and Drug Administration; 2018 [Available from:  
407 [https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-](https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers)  
408 [system-faers](https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers).
- 409 18. Instructions for Completing Form FDA 3500: U.S. Food and Drug Administration; 2022  
410 [Available from: [https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-](https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-completing-form-fda-3500#B2)  
411 [completing-form-fda-3500#B2](https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-completing-form-fda-3500#B2).
- 412 19. Berthold MR, Cebon N, Dill F, Gabriel TR, Kötter T, Meinel T, et al., editors. KNIME:  
413 The Konstanz Information Miner2008; Berlin, Heidelberg: Springer Berlin Heidelberg.
- 414 20. Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A Standardized Dataset  
415 of a Spontaneous Adverse Event Reporting System. *Healthcare (Basel)*. 2022;10(3).
- 416 21. Zhou ZX, Yin XD, Zhang Y, Shao QH, Mao XY, Hu WJ, et al. Antifungal Drugs and  
417 Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting  
418 System Database. *Front Pharmacol*. 2022;13:891336.
- 419 22. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal  
420 generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf*.  
421 2001;10(6):483-6.
- 422 23. Amacher DE. Female gender as a susceptibility factor for drug-induced liver injury. *Hum*  
423 *Exp Toxicol*. 2014;33(9):928-39.
- 424 24. Trikafta Package Insert. Boston, MA: Vertex Pharmaceuticals, Inc; 2023.
- 425 25. Rana P, Aleo MD, Wen X, Kogut S. Hepatotoxicity reports in the FDA adverse event  
426 reporting system database: A comparison of drugs that cause injury. *Acta Pharm Sin B*.  
427 2021;11(12):3857-68.
- 428 26. McEuen K, Borlak J, Tong W, Chen M. Associations of Drug Lipophilicity and Extent of  
429 Metabolism with Drug-Induced Liver Injury. *Int J Mol Sci*. 2017;18(7).
- 430 27. Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, et al. Data Mining at  
431 FDA -- White Paper: US Food and Drug Administration; 2018 [
- 432 28. Pannu V, Udongwo N, Imburgio S, Johal A, Mararenko A, Pozdniakova H, et al.  
433 Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database.  
434 *Ann Pharmacother*. 2023;10600280231169256.
- 435 29. Lu W, Sun S, Wei J, Thai S, Li D, Tang H, et al. Dipeptidyl peptidase-4 inhibitors and  
436 risk of venous thromboembolism: data mining of FDA adverse event reporting system. *Int J Clin*  
437 *Pharm*. 2020;42(5):1364-8.
- 438 30. Mazanetz MP, Goode CHF, Chudyk EI. Ligand- and Structure-Based Drug Design and  
439 Optimization using KNIME. *Curr Med Chem*. 2020;27(38):6458-79.
- 440 31. Dadi TH, Renard BY, Wieler LH, Semmler T, Reinert K. SLIMM: species level  
441 identification of microorganisms from metagenomes. *PeerJ*. 2017;5:e3138.
- 442 32. Hong E, Li R, Shi A, Almond LM, Wang J, Khudari AZ, et al. Safety of  
443 elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically  
444 based pharmacokinetic modeling and a clinical case series. *Pharmacotherapy*. 2023;43(4):291-9.

